Invivyd (NASDAQ:IVVD) Upgraded to Sell at Wall Street Zen

Invivyd logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Invivyd from “strong sell” to “sell.” Across analysts, the stock has a consensus “Hold” rating and an average price target of $10.
  • Invivyd shares were reported down 7.4%, opening at $0.41; that matches the stock’s one-year low, compared with a one-year high of $3.01.
  • The company reported a quarterly loss of $0.10 per share, narrower than analysts’ expected $0.13 loss, and revenue of $15.45 million, above estimates of $15.04 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Invivyd (NASDAQ:IVVD - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Invivyd in a report on Thursday, August 27th. HC Wainwright restated a "buy" rating on shares of Invivyd in a research note on Tuesday, September 29th. Weiss Ratings raised Invivyd from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 8th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Invivyd in a research report on Monday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Invivyd has an average rating of "Hold" and a consensus target price of $10.00.

Get Our Latest Stock Report on IVVD

Invivyd Trading Down 7.4%

IVVD stock opened at $0.41 on Friday. The stock has a 50-day moving average price of $0.69 and a two-hundred day moving average price of $1.06. Invivyd has a 1 year low of $0.41 and a 1 year high of $3.01.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its quarterly earnings results on Monday, November 16th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. The company had revenue of $15.45 million for the quarter, compared to analyst estimates of $15.04 million. Invivyd had a negative return on equity of 62.49% and a negative net margin of 214.77%. As a group, equities research analysts forecast that Invivyd will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Invivyd

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jupiter Topco LLC acquired a new stake in shares of Invivyd in the 2nd quarter valued at approximately $30,048,000. Janus Henderson Group PLC increased its holdings in Invivyd by 1.7% during the first quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company's stock worth $42,857,000 after buying an additional 551,188 shares during the last quarter. BlackRock Inc. acquired a new position in Invivyd during the second quarter worth $14,076,000. ADAR1 Capital Management LLC acquired a new position in Invivyd during the second quarter worth $3,322,000. Finally, Eversept Partners LP increased its holdings in Invivyd by 6.4% during the first quarter. Eversept Partners LP now owns 2,276,349 shares of the company's stock worth $2,959,000 after buying an additional 136,219 shares during the last quarter. Institutional investors own 70.36% of the company's stock.

Invivyd Company Profile

(Get Free Report)

Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company's lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.

Further Reading

Analyst Recommendations for Invivyd (NASDAQ:IVVD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Invivyd Right Now?

Before you consider Invivyd, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.

While Invivyd currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines